This site is intended for U.S. health care professionals only.

Patient assistance program

Available for qualified uninsured patients

For assistance, please call the ORBACTIV® Patient Assistance Program at:

1-844-ORBACTIV (1-844-672-2284)
Monday - Friday, 8:00 AM - 8:00 PM ET

orbactivassistanceprogram@themedco.com


Facilitating access to ORBACTIV® (oritavancin) for your patients

ORBACTIV® Patient Assistance Program guidelines

  • Patient is uninsured
  • Patient must meet household income requirements
  • The program is a replacement program for the unit used on the eligible patient
  • Both inpatients and outpatients may be eligible for the ORBACTIV® Patient Assistance Program

To download the ORBACTIV® Physician/Patient Assistance Form, please click the PDF file below

Orbactiv® (oritavancin) for injection patient assistance form

DISCLAIMER

Content provided for informational purposes only. This information does not guarantee coverage or payment. Codes, coverage, and payment may vary from setting to setting, and from insurer to insurer. The provider submitting a claim is solely responsible for the accuracy of the codes submitted and for compliance with all coverage and reimbursement policies.

Decisions to prescribe ORBACTIV® are by providers working with their patients. The ORBACTIV® Assistance Program provides information about ORBACTIV® and about assistance that may be available to patients who meet certain criteria, including that they are not insured by a federal health care program. More information is available through the ORBACTIV® Assistance Program.

The Medicines Company does not guarantee, and assumes no responsibility for the quality, availability, or scope of the ORBACTIV® Assistance Program services. The Medicines Company reserves the right to rescind, revoke, or amend this offer at any time without notice. Void where prohibited by law.

Important Safety Information

Contraindications

Use of intravenous unfractionated heparin sodium is contraindicated for 120 hours (5 days) after ORBACTIV® administration because the activated partial thromboplastin time (aPTT) test results are expected to remain falsely elevated for approximately 120 hours (5 days) after ORBACTIV® administration.

ORBACTIV® is contraindicated in patients with known hypersensitivity to ORBACTIV®.

Warnings and Precautions

Coagulation test interference: ORBACTIV® has been shown to artificially prolong aPTT for up to 120 hours, and may prolong PT and INR for up to 12 hours, ACT for up to 24 hours, and D-dimer for up to 72 hours.

Hypersensitivity reactions have been reported with the use of antibacterial agents including ORBACTIV®. Discontinue infusion if signs of acute hypersensitivity occur. Monitor closely patients with known hypersensitivity to glycopeptides.

Infusion-related reactions have been reported. Slow the rate or interrupt infusion if infusion reaction develops.

Clostridium difficile-associated colitis: Evaluate patients if diarrhea occurs.

Concomitant warfarin use: Patients should be monitored for bleeding if concomitantly receiving ORBACTIV® and warfarin.

Osteomyelitis: Institute appropriate alternate antibacterial therapy in patients with confirmed or suspected osteomyelitis.

Prescribing ORBACTIV® in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.

Adverse Reactions

The most common adverse reactions (≥3%) in patients treated with ORBACTIV® were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.

See Full Prescribing Information

www.orbactiv.com

This site is intended for U.S. Healthcare Professionals. If you are a U.S. Healthcare Professional, click OK to continue.

Ok
Cancel